U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O3
Molecular Weight 138.1207
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Salicylic acid

SMILES

OC(=O)C1=C(O)C=CC=C1

InChI

InChIKey=YGSDEFSMJLZEOE-UHFFFAOYSA-N
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.1207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid].
1999 Feb
Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE).
1999 May
False-high blood salicylate levels in neonates with hyperbilirubinemia.
2000 Dec
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Unraveling regulatory networks in plant defense using microarrays.
2001
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death.
2001 Apr
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
2001 Apr 17
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.
2001 Apr 30
Induction of wound response gene expression in tomato leaves by ionophores.
2001 Feb
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.
2001 Feb
Ethylene-dependent salicylic acid regulates an expanded cell death response to a plant pathogen.
2001 Feb
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics.
2001 Feb
Molecular responses to aphid feeding in Arabidopsis in relation to plant defense pathways.
2001 Feb
The spinning disc reactor--studies on a novel TiO2 photocatalytic reactor.
2001 Feb
Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals.
2001 Feb 1
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens.
2001 Feb 28
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane.
2001 Jan
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate.
2001 Jan
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action.
2001 Jan
Guidelines for the management of cutaneous warts.
2001 Jan
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
2001 Jan
Ion channel-forming alamethicin is a potent elicitor of volatile biosynthesis and tendril coiling. Cross talk between jasmonate and salicylate signaling in lima bean.
2001 Jan
The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drug.
2001 Jan
Induction of cell death in arabidopsis by superoxide in combination with salicylic acid or with protein synthesis inhibitors.
2001 Jan 1
Reversed-phase high-performance liquid chromatography versus spectrophotometric assay for thimerosal in Cuban recombinant hepatitis B vaccine.
2001 Jan 12
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data.
2001 Jan 16
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers.
2001 Jan 5
Broad-spectrum mildew resistance in Arabidopsis thaliana mediated by RPW8.
2001 Jan 5
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.
2001 May
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals.
2001 May
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.
2001 May
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen.
2001 May 11
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.
2001 May 8
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:43 GMT 2023
Edited
by admin
on Fri Dec 15 15:12:43 GMT 2023
Record UNII
O414PZ4LPZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Salicylic acid
EP   GREEN BOOK   HSDB   INCI   JAN   MART.   MI   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
LAMIVUDINE IMPURITY C [EP IMPURITY]
Common Name English
SALICYLIC ACID [USP-RS]
Common Name English
2-HYDROXYBENZENECARBOXYLIC ACID
Systematic Name English
COMPOUND W
Brand Name English
SALICYLIC ACID [EP IMPURITY]
Common Name English
SALICYLIC ACID [USP]
Common Name English
SALICYLIC ACID [JAN]
Common Name English
SALICYLIC ACID [VANDF]
Common Name English
SALICYLIC ACID [INCI]
Common Name English
DR. SCHOLL'S CALLUS REMOVERS
Brand Name English
SALICYLICUM ACIDUM
HPUS  
Common Name English
FEMA NO. 3985
Code English
SALICYLIC ACID [USP MONOGRAPH]
Common Name English
SALICYLIC ACID [MART.]
Common Name English
SULFASALAZINE IMPURITY H [EP IMPURITY]
Common Name English
SALICYLICUM ACIDUM [HPUS]
Common Name English
SALICYLIC ACID [GREEN BOOK]
Common Name English
SALICYLIC ACID [MI]
Common Name English
ACETYLSALICYLIC ACID IMPURITY C [EP IMPURITY]
Common Name English
SALICYLIC ACID [HSDB]
Common Name English
NSC-180
Code English
2-HYDROXYBENZOIC ACID [FHFI]
Common Name English
CARBASALATE CALCIUM IMPURITY C [EP IMPURITY]
Common Name English
Salicylic acid [WHO-DD]
Common Name English
DL-LYSINE ACETYLSALICYLATE IMPURITY A [EP IMPURITY]
Common Name English
2-HYDROXYBENZOIC ACID
FHFI  
Systematic Name English
ACIDUM SALICYLICUM [WHO-IP LATIN]
Common Name English
SALICYLIC ACID [EP MONOGRAPH]
Common Name English
SALICYLIC ACID [WHO-IP]
Common Name English
K-557
Code English
MESALAZINE IMPURITY H [EP IMPURITY]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 358.710
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
CFR 21 CFR 333.310
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
NCI_THESAURUS C52588
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
CFR 21 CFR 358.510
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
WHO-VATC QD01AE12
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
CFR 21 CFR 862.3830
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
EPA PESTICIDE CODE 76602
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
CFR 21 CFR 358.720
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
WHO-VATC QS01BC08
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
WHO-ATC S01BC08
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
CFR 21 CFR 358.110
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
FDA ORPHAN DRUG 359211
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
WHO-VATC QM02AC99
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
JECFA EVALUATION 2-HYDROXYBENZOIC ACID
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
WHO-ATC D01AE12
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
Code System Code Type Description
RXCUI
9525
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
PRIMARY
JECFA MONOGRAPH
891
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
HSDB
672
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
FDA UNII
O414PZ4LPZ
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
PUBCHEM
338
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
RXCUI
9522
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
ALTERNATIVE
RS_ITEM_NUM
1609002
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
LACTMED
Salicylic Acid
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
EVMPD
SUB15180MIG
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
WIKIPEDIA
SALICYLIC ACID
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
PRIMARY
CAS
69-72-7
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
WIKIPEDIA
Medical uses of salicylic acid
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-712-3
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
MESH
D020156
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
CHEBI
30762
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
IUPHAR
4306
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
NSC
180
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
SMS_ID
100000090038
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
PRIMARY
DRUG CENTRAL
2416
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
CHEBI
16914
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
DAILYMED
O414PZ4LPZ
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
MERCK INDEX
m9739
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C61934
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SALICYLIC ACID
Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023
PRIMARY Description: Colourless crystals, usually needle-like, or a white, crystalline powder; odourless. Solubility: Slightly soluble in water; soluble in 4 parts of ethanol (~750 g/l) TS and in 3 parts of ether R. Category: Keratolytic. Storage: Salicylic acid should be kept in a well-closed container. Definition: Salicylic acid contains not less than 99.0% and not more than 101.0% of C7H6O3, calculated with reference to the dried substance.
ChEMBL
CHEMBL424
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
DRUG BANK
DB00936
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
EPA CompTox
DTXSID7026368
Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Salicylic acid content for water extract of plant callus was 3.22+/-0.06 as expressed as mg/100 g of dry base of extract. For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
DERIVATIVE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PARENT -> METABOLITE ACTIVE
MINOR
URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
USP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY